| Item | Cat. No. | Application | Isotype |
| Anti-HTRA1 mAbs [Galegenimab Biosimilar] (MABL-4736) | MABL-4736 | ELISA, FACS, Functional assay, in vivo binding | G1, Kappa |
| Anti-B7/CD80/CD28LG mAbs [Galiximab Biosimilar] (MABL-4737) | MABL-4737 | ELISA, FACS, Functional assay, in vivo binding | G1, Lambda |
| Anti-IL17A and IL17F;ALB mAbs [Galvokimig1 Biosimilar] (MABL-4738) | MABL-4738 | ELISA, FACS, Functional assay, in vivo binding | G1;na, Kappa;Kappa |
| Anti-IL13 mAbs [Galvokimig2 Biosimilar] (MABL-4739) | MABL-4739 | ELISA, FACS, Functional assay, in vivo binding | na, Kappa |
| Anti-ERBB2/CD340/HER2 mAbs [Gancotamab Biosimilar] (MABL-4740) | MABL-4740 | ELISA, FACS, Functional assay, in vivo binding | na, Lambda |
| Anti-HGF/SF mAbs [Ficlatuzumab Biosimilar] (MABL-4710) | MABL-4710 | ELISA, FACS, Functional assay, in vivo binding | G1, Kappa |
| Anti-PDCD1/CD279/PD1;ERBB2/CD340/HER2 mAbs [Fidasimtamab Biosimilar] (MABL-4711) | MABL-4711 | ELISA, FACS, Functional assay, in vivo binding | G1;G1, Kappa;Kappa |
| Anti-IGF1R/CD221 mAbs [Figitumumab Biosimilar] (MABL-4712) | MABL-4712 | ELISA, FACS, Functional assay, in vivo binding | G2, Kappa |
| Anti-PDCD1/CD279/PD1 mAbs [Finotonlimab Biosimilar] (MABL-4713) | MABL-4713 | ELISA, FACS, Functional assay, in vivo binding | G4, Kappa |
| Anti-CTLA4/CD152 mAbs [Firastotug Biosimilar] (MABL-4714) | MABL-4714 | ELISA, FACS, Functional assay, in vivo binding | G1, Kappa |
| Anti-Influenza A HA mAbs [Firivumab Biosimilar] (MABL-4715) | MABL-4715 | ELISA, FACS, Functional assay, in vivo binding | G1, Kappa |
| Anti-IL1B mAbs [Firsekibart Biosimilar] (MABL-4716) | MABL-4716 | ELISA, FACS, Functional assay, in vivo binding | G4, Lambda |
| Anti-Human Herpesvirus Glycoprotein B AD-1 mAbs [Fiztasovimab Biosimilar] (MABL-4717) | MABL-4717 | ELISA, FACS, Functional assay, in vivo binding | G1, Lambda |
| Anti-TYRP1 mAbs [Flanvotumab Biosimilar] (MABL-4718) | MABL-4718 | ELISA, FACS, Functional assay, in vivo binding | G1, Kappa |
| Anti-IL20 mAbs [Fletikumab Biosimilar] (MABL-4719) | MABL-4719 | ELISA, FACS, Functional assay, in vivo binding | G4, Kappa |
| Anti-IL3RA/CD123;CD3E mAbs [Flotetuzumab Biosimilar] (MABL-4720) | MABL-4720 | ELISA, FACS, Functional assay, in vivo binding | na;na, Kappa;Lambda |
| Anti-IFNG mAbs [Fontolizumab Biosimilar] (MABL-4721) | MABL-4721 | ELISA, FACS, Functional assay, in vivo binding | G1, Kappa |
| Anti-CD3E mAbs [Foralumab Biosimilar] (MABL-4722) | MABL-4722 | ELISA, FACS, Functional assay, in vivo binding | G1, Kappa |
| Anti-Rabies Virus Antigenic Site III mAbs [Foravirumab Biosimilar] (MABL-4723) | MABL-4723 | ELISA, FACS, Functional assay, in vivo binding | G1, Kappa |
| Anti-GPRC5D;CD3E mAbs [Forimtamig Biosimilar] (MABL-4724) | MABL-4724 | ELISA, FACS, Functional assay, in vivo binding | G1;G1, Kappa;Lambda |
联系我们
Copyright © 2012-2029 西安迈博睿(Mabioway)生物科技有限公司 版权所有
地址:陕西省西安市浐灞生态区广运潭大道南段4555号长安大学科技园4号楼A单元2层
电话:15339069646 邮箱:info@mabioway.cn
